Clinical predictors of survival in men with castration-resistant prostate cancer: Evidence that Gleason score 6 cancer can evolve to lethal disease

Cancer

Volumn 119, Issue 16, 2013, Pages 2990-2998

  Nakabayashi, Mari ^a   Hayes, Julia ^a   Taplin, Mary Ellen ^a   Lefebvre, Patrick ^b   Lafeuille, Marie Helene ^b   Pomerantz, Mark ^a   Sweeney, Christopher ^a   Duh, Mei Sheng ^b   Kantoff, Philip W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ANALYSIS GROUP   (United States)

Author keywords

biopsy Gleason score; castration resistant prostate cancer; clinical predictors; overall survival; prostate specific antigen

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATECTOMY; RETROSPECTIVE STUDY; SEQUENTIAL SECONDARY HORMONAL THERAPY; SURVIVAL TIME;

EID: 84881474287     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28102     Document Type: Article

References (16)

1. Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011; 17: 4854-4861.
2. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-422.
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512.
4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-1520.
5. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002; 20: 3972-3982.
6. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003; 21: 1232-1237.
7. Armstrong AJ, Garrett-Mayer E, de Wit R, et al. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010; 16: 203-211.
8. Nakabayashi M, Werner L, Oh WK, et al. Secondary hormonal therapy in men with castration-resistant prostate cancer. Clin Genitourin Cancer. 2011; 9: 95-103.
9. Oh WK, Hayes J, Evan C, et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer. 2006; 5: 61-66.
10. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007; 25: 3965-3970.
11. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006; 98: 516-521.
12. Lin DY, Fleming TR, De Gruttola V,. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med. 1997; 16: 1515-1527.
13. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367: 203-213.
14. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005; 97: 1248-1253.
15. Lavery HJ, Droller MJ,. Do Gleason patterns 3 and 4 prostate cancer represent separate disease States? J Urol. 2012; 188: 1667-1675.
16. Pan CC, Potter SR, Partin AW, Epstein JI,. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol. 2000; 24: 563-569.